Tagged with Access

Spain Sergio Rodriguez, CEO of Pfizer Spain, highlights the strength of the affiliate and the importance for the company in Europe, as well as the key areas that are driving their growth. Furthermore, he gives an overview of the need for innovative companies to partner with key stakeholders and illustrates what…

France Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also shares insights into his career and the learnings from the Levothyrox case.   Overall, we are a very important branch…

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

Spain Ramón Villamarín Valdenebro, general manager of Shionogi Spain, highlights the key steps that needed to be taken to establish the affiliate over the last 18 months and his plans to grow its portfolio, both in the pharmacy and hospital sector. Furthermore, he gives an overview of how the company has…

Korea Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for GSK – vaccines, HIV and respiratory treatments, and provides an insight into how GSK can best utilize Korea’s strong environment…

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Korea Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea.   At the moment the main concern is that Korean prices are too low Could you provide our readers with an introduction to…

France Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience.   We are the only specialty pharma player exclusively dedicated to neuroscience and it is important that this shines through in our dealings…

Spain Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches on the importance of the market access team in the fragmented Spanish healthcare ecosystem and his ambitions for Allergan throughout…

Malaysia Ewe Kheng Huat, executive director of PhAMA, the Malaysian association for innovative companies, describes the current market environment for innovative medicines in Malaysia, from the difficulties to enter the Malaysian market to the great opportunities the country can offer in terms of clinical research and shared services.   We believe…

Malaysia Lance Duan, general manager of Roche Malaysia, discusses the dynamic changes in the country’s health system and the possibilities that exist for Roche to establish a collaborative relationship with the new government. Duan also describes the many initiatives Roche has to support Malaysian patients from a varying degree of angles,…

Algeria Loic Galmard discusses the opportunities and challenges of setting up local production in Algeria, and the best strategies to increase market access and create a dialogue with the regulatory authorities. What are your first impressions of the local market in the 10 months that you have been here so far?…